Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
88 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Low Back Pain - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Pipeline Review, H2 2016, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape. Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Low Back Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 7, 3, 3 and 2 respectively for Low Back Pain. Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Low Back Pain Overview 8 Therapeutics Development 9 Pipeline Products for Low Back Pain - Overview 9 Low Back Pain - Therapeutics under Development by Companies 10 Low Back Pain - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Low Back Pain - Products under Development by Companies 15 Low Back Pain - Companies Involved in Therapeutics Development 16 Adynxx, Inc. 16 Aestus Therapeutics, Inc. 17 Array BioPharma Inc. 18 Axsome Therapeutics Inc 19 Boehringer Ingelheim GmbH 20 Egalet Corporation 21 Frontier Biotechnologies Co., Ltd 22 Gador S.A. 23 Grunenthal GmbH 24 Hisamitsu Pharmaceutical Co., Inc. 25 Immune Pharmaceuticals Inc. 26 KPI Therapeutics, Inc. 27 MD Biosciences GmbH 28 Mesoblast Limited 29 Nektar Therapeutics 30 Orion Oyj 31 Pacira Pharmaceuticals, Inc. 32 Pfizer Inc. 33 Stayble Therapeutics AB 34 Sun Pharma Advanced Research Company Ltd. 35 Low Back Pain - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Combination Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 (loxoprofen + methocarbamol) - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 AB-001 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 ARRY-954 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 ATX-09002 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 AYX-2 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 bupivacaine - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 cebranopadol - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 dexmedetomidine hydrochloride - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Drug for Chronic Low Back Pain - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 HP-3150 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 IG-8801 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 lidocaine hydrochloride - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 MD-22 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 MPC-06ID - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 NKTR-181 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 oxycodone hydrochloride ER - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 SPARC-1401 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 tanezumab - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 U-2902 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 zoledronic acid - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Low Back Pain - Dormant Projects 80 Low Back Pain - Discontinued Products 82 Low Back Pain - Product Development Milestones 83 Featured News & Press Releases 83 Aug 01, 2016: MesoblastS Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science 83 Jun 22, 2016: Frontier Biotech Reports Primary Endpoint Met in Phase 2 Trial of AB001 In Chronic Low Back Pain 84 Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms 84 Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain 85 Appendix 87 Methodology 87 Coverage 87 Secondary Research 87 Primary Research 87 Expert Panel Validation 87 Contact Us 87 Disclaimer 88
List of Tables
Number of Products under Development for Low Back Pain, H2 2016 9 Number of Products under Development by Companies, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Products under Development by Companies, H2 2016 15 Low Back Pain - Pipeline by Adynxx, Inc., H2 2016 16 Low Back Pain - Pipeline by Aestus Therapeutics, Inc., H2 2016 17 Low Back Pain - Pipeline by Array BioPharma Inc., H2 2016 18 Low Back Pain - Pipeline by Axsome Therapeutics Inc, H2 2016 19 Low Back Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2016 20 Low Back Pain - Pipeline by Egalet Corporation, H2 2016 21 Low Back Pain - Pipeline by Frontier Biotechnologies Co., Ltd, H2 2016 22 Low Back Pain - Pipeline by Gador S.A., H2 2016 23 Low Back Pain - Pipeline by Grunenthal GmbH, H2 2016 24 Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 25 Low Back Pain - Pipeline by Immune Pharmaceuticals Inc., H2 2016 26 Low Back Pain - Pipeline by KPI Therapeutics, Inc., H2 2016 27 Low Back Pain - Pipeline by MD Biosciences GmbH, H2 2016 28 Low Back Pain - Pipeline by Mesoblast Limited, H2 2016 29 Low Back Pain - Pipeline by Nektar Therapeutics, H2 2016 30 Low Back Pain - Pipeline by Orion Oyj, H2 2016 31 Low Back Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016 32 Low Back Pain - Pipeline by Pfizer Inc., H2 2016 33 Low Back Pain - Pipeline by Stayble Therapeutics AB, H2 2016 34 Low Back Pain - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 35 Assessment by Monotherapy Products, H2 2016 36 Assessment by Combination Products, H2 2016 37 Number of Products by Stage and Target, H2 2016 39 Number of Products by Stage and Mechanism of Action, H2 2016 41 Number of Products by Stage and Route of Administration, H2 2016 43 Number of Products by Stage and Molecule Type, H2 2016 45 Low Back Pain - Dormant Projects, H2 2016 80 Low Back Pain - Dormant Projects (Contd..1), H2 2016 81 Low Back Pain - Discontinued Products, H2 2016 82
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.